These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 29290649)
1. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. Kanda T; Nirei K; Matsumoto N; Higuchi T; Nakamura H; Yamagami H; Matsuoka S; Moriyama M World J Gastroenterol; 2017 Dec; 23(46):8120-8127. PubMed ID: 29290649 [TBL] [Abstract][Full Text] [Related]
2. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world. Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F; J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors. Fedorchenko SV; Martynovych T; Klimenko Z; Solianyk I J Med Virol; 2021 Aug; 93(8):4975-4981. PubMed ID: 33704798 [TBL] [Abstract][Full Text] [Related]
4. Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir. Kitrinos KM; Corsa AC; Worth A; Hedskog C; Brainard DM; Miller MD; Mo H J Viral Hepat; 2018 Feb; 25(2):126-133. PubMed ID: 28833932 [TBL] [Abstract][Full Text] [Related]
5. Hepatitis C Virus Resistance Testing in Genotype 1: The Changing Role in Clinical Utility. Molino S; Martin MT Ann Pharmacother; 2017 Sep; 51(9):811-816. PubMed ID: 28480743 [TBL] [Abstract][Full Text] [Related]
7. Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review. Onorato L; Pisaturo M; Starace M; Minichini C; Di Fraia A; Astorri R; Coppola N Viruses; 2021 Mar; 13(3):. PubMed ID: 33800289 [TBL] [Abstract][Full Text] [Related]
9. Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome. Fahnøe U; Pedersen MS; Sølund C; Ernst A; Krarup HB; Røge BT; Christensen PB; Laursen AL; Gerstoft J; Thielsen P; Madsen LG; Pedersen AG; Schønning K; Weis N; Bukh J J Viral Hepat; 2021 Feb; 28(2):302-316. PubMed ID: 33131178 [TBL] [Abstract][Full Text] [Related]
10. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256 [TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing analysis of hepatitis C virus resistance-associated substitutions in direct-acting antiviral failure in South Korea. Kim KA; Lee S; Park HJ; Jang ES; Lee YJ; Cho SB; Kim YS; Kim IH; Lee BS; Chung WJ; Ahn SH; Kim S; Jeong SH Clin Mol Hepatol; 2023 Apr; 29(2):496-509. PubMed ID: 36880209 [TBL] [Abstract][Full Text] [Related]
12. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S; J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303 [TBL] [Abstract][Full Text] [Related]
13. Short article: Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience. Milazzo L; Magni C; Niero F; Schiavini M; Lai A; Cento V; Binda F; Antinori S; Sollima S Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1231-1234. PubMed ID: 28877086 [TBL] [Abstract][Full Text] [Related]
14. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. Hezode C; Reau N; Svarovskaia ES; Doehle BP; Shanmugam R; Dvory-Sobol H; Hedskog C; McNally J; Osinusi A; Brainard DM; Miller MD; Mo H; Roberts SK; O'Leary JG; Shafran SD; Zeuzem S J Hepatol; 2018 May; 68(5):895-903. PubMed ID: 29221887 [TBL] [Abstract][Full Text] [Related]
15. Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus. Li DK; Chung RT Methods Mol Biol; 2019; 1911():3-32. PubMed ID: 30593615 [TBL] [Abstract][Full Text] [Related]
16. High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life data. Gozlan Y; Bucris E; Shirazi R; Rakovsky A; Ben-Ari Z; Davidov Y; Veizman E; Saadi T; Braun M; Cohen-Naftaly M; Shlomai A; Shibolet O; Zigmond E; Katchman H; Menachem Y; Safadi R; Galun E; Zuckerman E; Nimer A; Hazzan R; Maor Y; Saif AM; Etzion O; Lurie Y; Mendelson E; Mor O Antivir Ther; 2019; 24(3):221-228. PubMed ID: 30880684 [TBL] [Abstract][Full Text] [Related]
17. Direct acting antivirals failure: cause and retreatment options. Parlati L; Pol S Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1245-1250. PubMed ID: 30791789 [TBL] [Abstract][Full Text] [Related]
18. Treatment of hepatitis C virus genotype 3-infection. Pol S; Vallet-Pichard A; Corouge M Liver Int; 2014 Feb; 34 Suppl 1():18-23. PubMed ID: 24373074 [TBL] [Abstract][Full Text] [Related]
19. Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C. Childs K; Davis C; Cannon M; Montague S; Filipe A; Tong L; Simmonds P; Smith D; Thomson EC; Dusheiko G; Agarwal K J Hepatol; 2019 Dec; 71(6):1099-1105. PubMed ID: 31400349 [TBL] [Abstract][Full Text] [Related]